SCHEMBL4152662

SCHEMBL4152662

O=C(Nc1ccc(N2CCCCC2)cc1)c1ccnc2[nH]c(-c3ccccc3)nc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 13/20 0.54
MAPT P10636 11/20 0.54
NPC1 O15118 11/20 0.54
SMN1; SMN2 Q16637 8/20 0.54
PKM P14618 2/20 0.54
HTT P42858 1/20 0.54
KLF5 Q13887 1/20 0.54
ALDH1A1 P00352 5/20 0.53
TP53 P04637 3/20 0.52
NFKB1 P19838 1/20 0.52
NFKB2 Q00653 1/20 0.52
RELA Q04206 1/20 0.52
MAPK1 P28482 3/20 0.51
TDP1 Q9NUW8 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
GAA P10253 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
LMNA P02545 1/20 0.51
GFER P55789 3/20 0.49
MCL1 Q07820 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4149998 0.90 RAB9A (0.54) RAB9AMAPTNPC1SMN1; SMN2PKM
SCHEMBL4152109 0.87 GSK3B (0.53) RAB9AMAPTNPC1SMN1; SMN2PKM
SCHEMBL4152711 0.87 MAPK10 (0.54) RAB9AMAPTNPC1SMN1; SMN2ALDH1A1
SCHEMBL4161584 0.86 RAB9A (0.51) RAB9AMAPTNPC1SMN1; SMN2ALDH1A1
SCHEMBL4158991 0.86 GSK3B (0.54) RAB9AMAPTNPC1SMN1; SMN2PKM
SCHEMBL4152155 0.85 GSK3B (0.48) MAPTALDH1A1GAALMNAGSK3B
SCHEMBL4145805 0.85 GSK3B (0.55) RAB9AMAPTNPC1SMN1; SMN2PKM
SCHEMBL4146035 0.84 PTPN11 (0.52) RAB9AMAPTNPC1SMN1; SMN2HTT
SCHEMBL4149979 0.83 PRMT5 (0.57) POLBJAK2
SCHEMBL4157085 0.82 PDE4B (0.48) RAB9AMAPTNPC1SMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 RAB9A 2749/4885MAPT 119/4885NPC1 2497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.